Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653210 | 0.84 | CFTR (0.41) | — | |
| SCHEMBL14041493 | 0.82 | BAZ2B (0.47) | BAZ2BACHEALDH1A1GAAMAPT | |
| SCHEMBL4652083 | 0.81 | HTR2A (0.45) | BAZ2BACHEALDH1A1MAPT | |
| SCHEMBL4651124 | 0.81 | HTR2A (0.45) | BAZ2BACHEALDH1A1MAPT | |
| SCHEMBL4651981 | 0.81 | CFTR (0.43) | GAA | |
| SCHEMBL4651181 | 0.81 | BAZ2B (0.51) | BAZ2BMAPT | |
| SCHEMBL4650789 | 0.80 | AR (0.45) | ALDH1A1TDP1 | |
| SCHEMBL14216282 | 0.75 | BAZ2B (0.45) | BAZ2BACHEMAPT | |
| SCHEMBL2430644 | 0.75 | BAZ2B (0.47) | BAZ2BACHEALDH1A1GAA | |
| SCHEMBL4652024 | 0.74 | MAPK10 (0.36) | MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275083-A1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES | BAYER SCHERING PHARMA AG (DE) | 2008-11-06 | — | — | US | claimed |
| EP-1975159-A1 | 2,3,4,9-Tetrahydro-1H-carbazoles | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-01 | — | — | EP | claimed |
| US-20080275083-A1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES | BAYER SCHERING PHARMA AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008116671-A1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1975159-A1 | 2,3,4,9-Tetrahydro-1H-carbazoles | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275083-A1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES | FSHR, GNRHR, CYP19A1 | BAZ2B 1405/4885ACHE 972/4885SIGMAR1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.